Langerhans cell sarcoma (LCS), a rare malignant neoplasm in the general category of myeloid neoplasms characterized by overtly malignant Langerhans cells (LC) with conspicuous mitotic activity including atypical forms. Although most cases occur in adults, rare examples of LCS have been reported in children with variable clinical outcome. We present 2 childhood cases of Langerhans cell neoplasm with high grade sarcomatous features and OSBPL9::BRAF fusion and BRAF V600E mutation.
CollinMMilneP.Langerhans cell origin and regulation. Curr Opin Hematol. 2016;23(1):28-35.
2.
CampoEJaffeESCookJR, et alThe International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022;140(11):1229-1253.
3.
KhouryJDSolaryEAblaO, et alThe 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703-1719.
4.
BledsoeJR PJDehnerLP, et alLangerhans cell proliferations and related disorders (“L” group). 2nd edn.Wolters Kluwer; 2023.
5.
KrooksJMinkovMWeatherallAG.Langerhans cell histiocytosis in children: history, classification, pathobiology, clinical manifestations, and prognosis. J Am Acad Dermatol. 2018;78(6):1035-1044.
6.
AllenCELadischSMcClainKL.How I treat Langerhans cell histiocytosis. Blood. 2015;126(1):26-35.
RisdallRJDehnerLPDurayPKobrinskyNRobisonLNesbitMEJr.Histiocytosis X (Langerhans’ cell histiocytosis). Prognostic role of histopathology. Arch Pathol Lab Med. 1983;107(2):59-63.
9.
RuanGJZanwarSRavindranA, et alClinical characteristics, molecular aberrations, treatments, and outcomes of malignant histiocytosis. Am J Hematol. 2024;99(5):871-879.
10.
SinghiADMontgomeryEA.Gastrointestinal tract langerhans cell histiocytosis: a clinicopathologic study of 12 patients. Am J Surg Pathol. 2011;35(2):305-310.
11.
EmileJFAblaOFraitagS, et alRevised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016;127(22):2672-2681.
12.
TellaSHKommalapatiARechKLGoRSGoyalG.Incidence, clinical features, and outcomes of langerhans cell sarcoma in the United States. Clin Lymphoma Myeloma Leuk. 2019;19(7):441-446.
13.
HowardJEDwivediRCMastersonLJaniP.Langerhans cell sarcoma: a systematic review. Cancer Treat Rev. 2015;41(4):320-331.
14.
PanZXuML.Histiocytic and dendritic cell neoplasms. Surg Pathol Clin. 2019;12(3):805-829.
15.
LauSKChuPGWeissLM.Immunohistochemical expression of Langerin in Langerhans cell histiocytosis and non-Langerhans cell histiocytic disorders. Am J Surg Pathol. 2008;32(4):615-619.
HowardJEMastersonLDwivediRCJaniP.Langerhans cell sarcoma of the head and neck. Crit Rev Oncol Hematol. 2016;99:180-188.
18.
ChungWDImSAChungNGParkGS.Langerhans cell sarcoma in two young children: imaging findings on initial presentation and recurrence. Korean J Radiol. 2013;14(3):520-524.
19.
LeeJSKoGHKimHCJangISJeonKNLeeJH.Langerhans cell sarcoma arising from Langerhans cell histiocytosis: a case report. J Korean Med Sci. 2006;21(3):577-580.
20.
YiWChenWYYangTXLanJPLiangWN.Langerhans cell sarcoma arising from antecedent Langerhans cell histiocytosis: a case report. Medicine (Baltimore). 2019;98(10):e14531.
21.
LuoB PBPengZ, et alPharyngeal tonsil manifestation of Langerhans cells sarcoma: a case report and review of the literature. Int J Pediatr Otorhinolaryngol Extra. 2011;6:156-158.
22.
SurendraHSPrabhudesaiSSrinivasanARamachandranBScottJX.Langerhans cell sarcoma presenting as a mediastinal mass in a young infant: a case report. Int J Pediatr Res2017;4:4.
23.
ZwerdlingTWonEShaneLJavaharaRJaffeR.Langerhans cell sarcoma: case report and review of world literature. J Pediatr Hematol Oncol. 2014;36(6):419-425.
24.
JainPSurreyLFStrakaJ, et alBRAF fusions in pediatric histiocytic neoplasms define distinct therapeutic responsiveness to RAF paradox breakers. Pediatr Blood Cancer. 2021;68(6):e28933.
25.
XieSShaoZShaoD, et alCase report: Langerhans cell sarcoma with intracranial and extracranial communication on the left frontal bone. Front Surg. 2022;9:882694.
26.
DurhamBHDiamondELAbdel-WahabO.Histiocytic neoplasms in the era of personalized genomic medicine. Curr Opin Hematol. 2016;23(4):416-425.
27.
EganCNicolaeALackJ, et alGenomic profiling of primary histiocytic sarcoma reveals two molecular subgroups. Haematologica. 2020;105(4):951-960.
28.
JouenneFReger de MouraCLorillonG, et alRASA1 loss in a BRAF-mutated Langerhans cell sarcoma: a mechanism of resistance to BRAF inhibitor. Ann Oncol. 2019;30(7):1170-1172.
29.
LuZZhangYFengDShengJYangWLiuB.Targeted next generation sequencing identifies somatic mutations and gene fusions in papillary thyroid carcinoma. Oncotarget. 2017;8(28):45784-45792.
30.
XerriLAdelaideJPopoviciC, et alCDKN2A/B deletion and double-hit mutations of the MAPK pathway underlie the aggressive behavior of Langerhans cell tumors. Am J Surg Pathol. 2018;42(2):150-159.
31.
TillitSCarbajal-MamaniSZloteckiR, et alLangerhans cell sarcoma of the vulva: case report and review of the literature. Gynecol Oncol Rep. 2020;32:100570.
